Chemotherapy for Prostate Cancer
Cardiovascular toxicities of systemic treatments of prostate cancer | Nature Reviews Urology
![PDF] Modern treatment of metastatic prostate cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6ce0a90e6587180ba0676081483bbfd434dc2604/2-Figure2-1.png "PDF] Modern treatment of metastatic prostate cancer. | Semantic Scholar")
PDF] Modern treatment of metastatic prostate cancer. | Semantic Scholar
FDA Approves Relugolix for Advanced Prostate Cancer - NCI
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design | JACC: CardioOncology
Clinical trials for docetaxel treatment in prostate cancer in EU... | Download Scientific Diagram
Prostate Cancer Treatment Options
Prostate Cancer - TREATMENT - Uroweb
Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations | Prostate Cancer and Prostatic Diseases
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial - The Lancet Oncology
circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3 | Biomarker Research | Full Text
Chemotherapy and Beyond: The Changing Face of Systemic Therapy for Prostate Cancer
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial - ScienceDirect
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data - The Lancet Oncology
Cancers | Free Full-Text | Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes
Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1: International Journal of Radiation Biology: Vol 0, No 0
Drugs For Prostate Cancer Treatment | Onco.com
Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases. | Semantic Scholar
New Pharmacotherapies in the Treatment of Advanced Prostate Cancer - Walid El-Ayass, Joelle El-Amm, Maneesh Jain, Jeanny B. Aragon-Ching, 2010
Diagnostics | Free Full-Text | Genome-Based Classification and Therapy of Prostate Cancer
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches | Journal of Urology
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial - ScienceDirect
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent
